Medindia

X

1st International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma

Tuesday, May 10, 2011 Respiratory Disease News J E 4
Advertisement

LOS ANGELES, May 9, 2011 /PRNewswire/ -- The UCLA Mesothelioma Research Program is sponsoring the 1st International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma (MPM) at the Sheraton Hotel in Santa Monica, California. This unique one-day symposium will take place on Saturday, May 21st from 8:00 a.m. to 5:00 p.m.

The course will be led by Dr. Robert Cameron, MD, FACS, Director of the Mesothelioma Research Program at the David Geffen School of Medicine at UCLA, Chief of Thoracic Surgery at the West Los Angeles Veterans' Administration Medical Center, and a long-time advocate for lung-sparing surgery.

The seminar's distinguished international faculty includes both Mr. Tom Treasure, MD and Mr. David A Waller, MD, who will discuss the recent results announced from the Mesothelioma and Radical Surgery (MARS) Trial conducted in the U.K. The program will feature additional experts in the fields of surgery, radiation, chemotherapy and pulmonary medicine. The symposium was designed primarily for physicians needing continuing medical education (CME) credit but other interested parties may attend.

For a brochure on the seminar and to enroll online, go to http://www.cme.ucla.edu/courses. To register by phone or for further information, call 310-794-2620.

Contact:

Clare CameronPacific Meso Center at PHLBI310-478-4678ccameron@phlbi.orghttp://www.pacificmesocenter.orghttp://www.phlbi.org

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE Pacific Meso Center at PHLBI

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
NxStage® Supports Initiative by Patient Advocacy G...
S
MarketsandMarkets: Global Respiratory Care Devices...